FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Delayed Börse Stuttgart 16:05:31 11/06/2024 BST | ||
| 47.5 EUR | -0.81% |
|
| Current month | +19.37% | ||
| 1 month | +29.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 11/06/24 | 47.5 | -0.81% |
| 10/06/24 | 47.89 | -0.29% |
| 07/06/24 | 48.03 | +0.97% |
| 06/06/24 | 47.57 | +4.11% |
| 05/06/24 | 45.69 | +2.33% |
Delayed Quote Börse Stuttgart
Last update June 11, 2024 at 04:05 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MF2MKM |
| ISIN | DE000MF2MKM3 |
| Date issued | 23/06/2017 |
| Strike | 241.7 $ |
| Maturity | Unlimited |
| Parity | 4.68 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 48.03 € |
|---|---|
| Lowest since issue | 8.24 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483.3
USD
Average target price
463.4
USD
Spread / Average Target
-4.11%
- Stock Market
- Certificates
- Certificat